GALLIUM Phase 3 trial

July 11, 2018July 11, 2018

Health Canada OKs Gazyva as First-line Therapy for Advanced Follicular Lymphoma

News

Patients in Canada who have advanced follicular lymphoma now can receive Gazyva (obinutuzumab) in combination with chemotherapy as first-line therapy, Roche Canada announced. Health Canada’s decision follows Gazyva’s approval in the ... Read more

November 7, 2017November 7, 2017

Study Links Early Progression to Poorer Survival Outcomes in Follicular Lymphoma Patients

News

New data from the GALLIUM Phase 3 trial (NCT01332968) shows that follicular lymphoma patients who progress within two years of immunochemotherapy have a 26-fold increased risk of death, compared to those ... Read more

September 26, 2017September 26, 2017

European Commission Approves Gazyvaro as First-Line Follicular Lymphoma Therapy

News

The European Commission has approved Roche’s Gazyvaro (obinutuzumab) for previously untreated patients with advanced follicular lymphoma. The treatment is approved in combination with chemotherapy and should be followed by Gazyvaro maintenance therapy. ... Read more